IC
PVLA

Ikarian Capital’s Palvella Therapeutics PVLA Stock Holding History

Ikarian Capital’s Portfolio PVLA Stock Details PVLA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q1 		– Sell
-275
Closed -$80K – 178
2019
Q4 		$80K Buy
+275
New +$76.2K 0.01% 109

Other funds holding PVLA

SCM
Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return
FLAM
First Light Asset Management Edina, Minnesota $1.12B AUM 114.45% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Ikarian Capital's PVLA Position: Q1 2026 in Review

Ikarian Capital opened a new position in Palvella Therapeutics (PVLA) in Q1 2026: 64,626 shares worth $8.06M. The stake represents 0.65% of the portfolio and ranks #42 among its holdings. This is a return to the name: Ikarian Capital previously reported a position in PVLA as recently as Q3 2025.

Ikarian Capital first reported a position in PVLA in Q3 2025 and has held it in 2 quarters since. 180 funds tracked by Wall St. Rank hold PVLA as of Q1 2026.

  • Ikarian Capital held 64,626 shares of Palvella Therapeutics worth $8.06M as of Q1 2026.
  • Palvella Therapeutics was a new Ikarian Capital position in Q1 2026.
  • Palvella Therapeutics made up 0.65% of Ikarian Capital's portfolio in Q1 2026, its #42 holding.
  • Ikarian Capital first reported a position in Palvella Therapeutics in Q3 2025 and has held it in 2 quarters since.
  • 180 funds tracked by Wall St. Rank held Palvella Therapeutics as of Q1 2026.

Based on Ikarian Capital's 13F filing for Q1 2026, filed 15 May 2026.